Journal of the Endocrine Society | 2021

Toxic Thyroid Nodule: To FNA or Not?

 
 
 
 

Abstract


Abstract Background: ATA guidelines recommend evaluation of hyperthyroidism with radioiodine scan and consideration of FNA for non-toxic nodules with suspicious sonographic features. However, there is no standard evidence-based approach to performing ultrasound in patients with toxic nodules. Recent studies have shown increased rates of thyroid cancer in patients with hyperthyroidism and has been shown to demonstrate aggressive histologic features. Clinical Case: A 41-year-old female presented to primary care provider for annual physical exam, found to have intermittent bigeminy and enlarged thyroid on exam. EKG notable for multiple premature ventricular complexes. Evaluation revealed suppressed TSH <0.01 µIU/mL (0.27-4.20), normal free T4 1.27 ng/dL (0.80-1.80), slightly elevated free T3 4.84 pg/mL (2.57-4.43) and elevated TSI 238% (<122). Methimazole was started for treatment of hyperthyroidism. Thyroid sonogram was ordered for abnormal exam, that showed 2.7 cm TIRADS 4 left thyroid nodule with microcalcifications. I-131 uptake values were 20% and 49% at 4-hours and 24-hours, respectively. Technetium-99M scan showed toxic autonomous nodule in the left thyroid lobe corresponding to the one seen on sonogram. The remainder of the thyroid gland showed heterogeneously suppressed uptake. FNA of the thyroid nodule was done due to the presence of microcalcifications and the cytopathology was suspicious for papillary carcinoma. She underwent total thyroidectomy with central neck dissection involving pre-tracheal and paratracheal lymph nodes (level VI). Pathology showed 1.4 cm papillary carcinoma with lymphovascular space invasion and multifocal papillary microcarcinomas in the left thyroid lobe, 0.2 cm papillary microcarcinoma in right thyroid lobe, metastatic papillary carcinoma in 2 out of 5 lymph nodes, largest metastatic deposit 0.1 cm in the largest dimension with no extra nodal extension. There was also follicular hyperplasia noted consistent with Graves’ disease. Post-operatively, she had thyrogen-stimulated adjuvant RAI treatment, dose 107.4 mCi. Post therapy scan did not show evidence of distant metastases. Conclusion: This case demonstrates the identification of a metastatic papillary thyroid carcinoma based on suspicious ultrasound features requiring total thyroidectomy, central neck dissection and adjunct radioactive iodine in a patient with hyperthyroidism from co-existent toxic thyroid nodule and Graves’ disease.

Volume 5
Pages A903 - A903
DOI 10.1210/jendso/bvab048.1843
Language English
Journal Journal of the Endocrine Society

Full Text